Drug Discovery · Frederiksberg, Denmark · Founded 2017 · Privately Held (backing)
Developer of antibody-drug conjugates designed to create new medicines for cancer patients with significant unmet needs. Adcendo is based in Frederiksberg, Denmark and was founded in 2017. It was valued at $210 million at its later-stage round in Nov 2024, the last priced event on record. It has raised $316 million across 2 recorded rounds; the latest was a $134 million Series B in Nov 2024.
PMV mark · valuation
$209.9M
Oct 2026
Priced at
its later-stage round
Nov 2024
Total raised
$315.9M
Last round
Later Stage VC (Series B)
Nov 2024
No prints on record
No secondary trades in Adcendo shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Adcendo with a free account
·The complete investor list: 21 names
·Watch Adcendo: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Adcendo stock.
